Redhill Biopharma (XTAE:RDHL) 3-Year Revenue Growth Rate : -75.70% (As of Jun. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Redhill Biopharma 3-Year Revenue Growth Rate?

Redhill Biopharma's Revenue per Share for the three months ended in Jun. 2023 was ₪0.02.

During the past 12 months, Redhill Biopharma's average Revenue per Share Growth Rate was -97.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was -75.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was -21.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was 58.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Redhill Biopharma was 995.50% per year. The lowest was -75.70% per year. And the median was 70.00% per year.

Competitive Comparison of Redhill Biopharma's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Redhill Biopharma's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's 3-Year Revenue Growth Rate falls into.

Redhill Biopharma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Redhill Biopharma (XTAE:RDHL) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Redhill Biopharma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma (XTAE:RDHL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (XTAE:RDHL) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

RDHL:USA 2RH0:Germany 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.